公开(公告)号：US11643464B2

公开(公告)日：2023-05-09

申请号：US16728587

申请日：2019-12-27

Applicant: Yeda Research and Development Co. Ltd

Inventor： Michal Eisenbach-Schwartz ,  Kuti Baruch ,  Neta Rosenzweig

IPC: C07K16/28 ,  A61K39/395 ,  A61P27/02 ,  A61K45/06 ,  A61K31/404 ,  A61K31/7068 ,  A61K31/4155 ,  A61K33/36 ,  A61K39/00

CPC classification number: C07K16/2818 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K39/395 ,  A61K39/39541 ,  A61K45/06 ,  C07K16/2803 ,  C07K16/2827 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2039/572 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/76 ,  A61K33/36 ,  A61K2300/00 ,  A61K31/404 ,  A61K2300/00 ,  A61K31/4155 ,  A61K2300/00 ,  A61K31/7068 ,  A61K2300/00

Abstract: The present specification discloses a pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS. The pharmaceutical composition is administered by a dosage regimen comprising at least one course of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.

公开(公告)号：US20220146534A1

公开(公告)日：2022-05-12

申请号：US17423769

申请日：2020-01-16

Applicant: Yeda Research and Development, Co., Ltd.

Inventor： Michal Eisenbach-Schwartz ,  Hila Ben-Yehuda ,  Michal Arad ,  Tommaso Croese ,  Javier Maria Peralta Ramos ,  Giulia Castellani ,  Neta Rosenzweig

IPC: G01N33/68 ,  G01N33/50

Abstract: A method for predicting whether a patient diagnosed with a disease, disorder, condition or injury of the CNS is likely to be responsive or non-responsive to treatment with an immune checkpoint modulator is provided, wherein said method comprises determining ex vivo, in a blood sample obtained from the patient, or in a fraction thereof, a biomarker selected from: (a) the level of a monocyte subpopulation expressing CCR2, CD204 or a combination thereof, or CCR2 and a marker selected from igf1, lyve1, Stab-1, Siglec1 and Mrc1, or any combination thereof, (b) the ratio of the level of a monocyte subpopulation (CD14+ cells) expressing CCR2highCX3CR1low to a monocyte subpopulation expressing CCR2lowCX3CR1high; (c) the level of a CCR2 agonist; and (d) the level of a CCR2 antagonist.

公开(公告)号：US20200332011A1

公开(公告)日：2020-10-22

申请号：US16852508

申请日：2020-04-19

Applicant: ImmunoBrain Checkpoint, Inc. ,  Yeda Research and Development Co. Ltd.

Inventor： Ester Yoles ,  Berit Olsen Krogh ,  Allan Jensen ,  Jan Egebjerg ,  Carol David ,  Kuti Baruch ,  Michal Eisenbach-Schwartz

IPC: C07K16/28

Abstract: The present specification discloses modified anti-PD-L1 antibodies that abolishes Fc-related effector function and enhances clearance rate while maintaining therapeutic efficacy for neurodegenerative disease modification. The present specification also discloses nucleic acid sequences and expression constructs encoding such modified anti-PD-L1 antibodies as well as methods of making such modified anti-PD-L1 antibodies. In addition, the present specification discloses methods of treatment and uses that employ an administration regime of the disclosed anti-PD-L1 antibodies that ensures the antibodies are present for only a specific period of time and then are sufficiently cleared from the body to ensure treatment efficacy is maintained.

公开(公告)号：US20190185563A1

公开(公告)日：2019-06-20

申请号：US16284081

申请日：2019-02-25

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Michal Eisenbach-Schwartz ,  Kuti Baruch ,  Neta Rosenzweig

IPC: C07K16/28 ,  A61K38/02 ,  A61K38/00 ,  A61K31/4155 ,  A61K38/16 ,  A61K38/18 ,  A61K38/20 ,  A61K38/14 ,  A61K45/06 ,  A61K31/404 ,  A61K39/395 ,  A61K33/36 ,  A61K31/7068

CPC classification number: C07K16/2803 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/005 ,  A61K38/02 ,  A61K38/14 ,  A61K38/168 ,  A61K38/18 ,  A61K38/208 ,  A61K39/395 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2121/00 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/75 ,  C07K2317/76 ,  A61K2300/00

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.

公开(公告)号：US20180111999A1

公开(公告)日：2018-04-26

申请号：US15821678

申请日：2017-11-22

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Michal Eisenbach-Schwartz ,  Kuti Baruch ,  Neta Rosenzweig

IPC: C07K16/28 ,  A61K45/06 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/02 ,  A61K38/14 ,  A61K38/16 ,  A61K38/18 ,  A61K38/20 ,  A61K31/404 ,  A61K39/395 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/005 ,  A61K38/02 ,  A61K38/14 ,  A61K38/168 ,  A61K38/18 ,  A61K38/208 ,  A61K39/395 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2121/00 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/75 ,  C07K2317/76 ,  A61K2300/00

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.

公开(公告)号：US20180111998A1

公开(公告)日：2018-04-26

申请号：US15821672

申请日：2017-11-22

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Michal Eisenbach-Schwartz ,  Kuti Baruch ,  Neta Rosenzweig

IPC: C07K16/28 ,  A61K45/06 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/14 ,  A61K38/16 ,  A61K38/18 ,  A61K31/404 ,  A61K39/395 ,  A61K38/20 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/005 ,  A61K38/02 ,  A61K38/14 ,  A61K38/168 ,  A61K38/18 ,  A61K38/208 ,  A61K39/395 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2121/00 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/75 ,  C07K2317/76 ,  A61K2300/00

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.

公开(公告)号：US09314483B2

公开(公告)日：2016-04-19

申请号：US14303212

申请日：2014-06-12

Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.

Inventor： Michal Eisenbach-Schwartz ,  Ester Yoles ,  Ravid Shechter ,  Omer Miller

IPC: C12N5/0786 ,  A61K35/15 ,  A61K35/14 ,  A61K35/12

CPC classification number: A61K35/15 ,  A61K35/14 ,  A61K2035/124 ,  C12N5/0645

Abstract: A subpopulation of peripheral blood mononuclear cells (PBMCs) that is substantially devoid of CD3+ cells, CD19+ cells, CD56+ cells and optionally of CD16+ cells, for use in treatment of CNS injury is provided.

Abstract translation: 提供了用于治疗CNS损伤的基本上不含CD3 +细胞，CD19 +细胞，CD56 +细胞和任选的CD16 +细胞的外周血单核细胞（PBMC）的亚群。

公开(公告)号：US20240069042A1

公开(公告)日：2024-02-29

申请号：US18387593

申请日：2023-11-07

Applicant: NeuroQuest Ltd. ,  Yeda Research and Development Co. Ltd. at the Weizmann Institute of Science

Inventor： Xin Huang ,  Yihan Li ,  James Doecke ,  Michal Eisenbach-Schwartz ,  Baijun Gu

IPC: G01N33/68 ,  G01N33/58

CPC classification number: G01N33/6896 ,  G01N33/582 ,  G01N2800/2821

Abstract: Compositions and kits for diagnosing and prognosing Alzheimer's Disease (AD) in a human patient include a binding agent such as a monoclonal antibody for a biomarker conjugated to a detectable moiety such as a fluorophore, wherein the biomarker is chosen from CD11c, CD59, CD91, and CD163 and other phagocytosis-related molecules. Further compositions and kits employ panels of fluorophore-conjugated monoclonal antibodies for biomarkers including scavenger receptors. Methods for determining the relative expression of biomarkers, diagnosing AD, and determining the efficacy of AD therapeutic candidates such as phagocytosis-promoting agents and scavenger receptor agonists also appear.

公开(公告)号：US11884727B2

公开(公告)日：2024-01-30

申请号：US17186960

申请日：2021-02-26

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Michal Eisenbach-Schwartz ,  Kuti Baruch ,  Neta Rosenzweig

IPC: C07K16/28 ,  A61K39/395 ,  A61P25/28 ,  A61P37/02 ,  A61K38/00 ,  A61K38/14 ,  A61K45/06 ,  A61K31/404 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/16 ,  A61K38/18 ,  A61K38/20 ,  A61K31/4155 ,  A61K38/02 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/005 ,  A61K38/02 ,  A61K38/14 ,  A61K38/168 ,  A61K38/18 ,  A61K38/208 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/39541 ,  A61K45/06 ,  C07K16/2818 ,  C07K16/2827 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2121/00 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/75 ,  C07K2317/76 ,  A61K38/208 ,  A61K2300/00 ,  A61K33/36 ,  A61K2300/00 ,  A61K31/404 ,  A61K2300/00 ,  A61K31/4155 ,  A61K2300/00 ,  A61K31/7068 ,  A61K2300/00

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.

公开(公告)号：US20230183350A1

公开(公告)日：2023-06-15

申请号：US17806187

申请日：2022-06-09

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Michal Eisenbach-Schwartz ,  Kuti Baruch ,  Neta Rosenzweig

IPC: C07K16/28 ,  A61K39/395 ,  A61K31/4155 ,  A61K31/7068 ,  A61K31/404 ,  A61K33/36 ,  A61K45/06 ,  A61P25/16 ,  A61P37/06 ,  A61P25/28 ,  A61P27/02

CPC classification number: C07K16/2827 ,  C07K16/2818 ,  C07K16/2803 ,  A61K39/3955 ,  A61K31/4155 ,  A61K39/395 ,  A61K39/39541 ,  A61K31/7068 ,  A61K31/404 ,  A61K33/36 ,  A61K45/06 ,  A61P25/16 ,  A61P37/06 ,  A61P25/28 ,  A61P27/02 ,  A61K2039/545

Abstract: The present specification discloses a pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS. The pharmaceutical composition is administered by a dosage regimen comprising at least one course of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.